ARCHIVES

Lilly Begins Phase III Trial Of Alimta In Extensive SCLC

This article is from The Cancer Letter archive.

Vol. 29 No. 10 | October 27, 2006

Download PDF Visit The Full Archive

Related Articles

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

July 26, 2002

Bailer NEJM “Irresponsible, Purposely Misleading,” Ignored Facts, DeVita Tells NCA

May 23, 1986

Research: No Increase in Cancer Deaths Found at Three Mile Island

May 5, 2000

Consensus conference On Cervical Cancer

January 26, 1996

Neulasta Reduces Incidence Of Febrile Neutropenia

February 22, 2013

Hilton Head, SC, Physician’s Files Subpoenaed By FBI

March 18, 1994